Zerlasiran is an investigational new drug that is being evaluated to treat atherosclerotic cardiovascular disease. It is small interfering RNA (siRNA) drug candidate designed to reduce levels of lipoprotein(a).
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.